Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Journal Article

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.

Full Text

Duke Authors

Cited Authors

  • Linke, K; Pazdur, R; Abbruzzese, JL; Ajani, JA; Winn, R; Bradof, JE; Daugherty, K; Levin, B

Published Date

  • November 1991

Published In

Volume / Issue

  • 9 / 4

Start / End Page

  • 353 - 356

PubMed ID

  • 1804812

Electronic International Standard Serial Number (EISSN)

  • 1573-0646

International Standard Serial Number (ISSN)

  • 0167-6997

Digital Object Identifier (DOI)

  • 10.1007/bf00183580

Language

  • eng